Skip to main content
Clinical Trials/CTRI/2024/04/065776
CTRI/2024/04/065776
Not yet recruiting
未知

A Prospective Observational Study to evaluate the Gut Microbiome status in Indian advanced Non-Small Cell Lung Cancer Patients receiving Immunotherapy and investigate potential correlations between the gut microbiome composition and treatment outcomes - NI

Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC)0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C34- Malignant neoplasm of bronchus andlung
Sponsor
Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC)
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC)

Eligibility Criteria

Inclusion Criteria

  • 1\. Those who were willing to participate (via written consent form) in the study.
  • 2\. Histologically confirmed diagnosis of non\-small cell lung cancer (NSCLC).
  • 3\. Age more than 18 years at the time of the study.
  • 4\. PD\-L1 tumor expression more than 1 percent
  • 5\. Adequate performance status (e.g., ECOG performance status of 0\-2\).
  • 6\. Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1\.1 (RECIST v1\.1\)
  • 7\. Prior systemic treatment for metastatic NSCLC will be allowed
  • 8\. Willingness and ability to undergo stool sample collection for gut microbiome analysis.
  • 9\. Patients scheduled to receive immunotherapy as part of their treatment.
  • 10\. Adequate organ function (e.g., liver, kidney, hematological parameters) to tolerate immunotherapy.

Exclusion Criteria

  • 1\. Previous exposure to immunotherapy or other immune checkpoint inhibitors.
  • 2\. Presence of other active malignancies or history of recent cancer treatment.
  • 3\. History of autoimmune diseases or immunodeficiency disorders.
  • 4\. Current use of antibiotics, probiotics, or other medications known to significantly affect the gut microbiome.
  • 5\. Severe gastrointestinal disorders or conditions that may impact gut microbiota composition (e.g., inflammatory bowel disease).
  • 6\. Inability to provide informed consent or comply with study procedures.
  • 7\. Contraindications to undergoing stool sample collection or microbial analysis (e.g., active gastrointestinal bleeding, recent bowel surgery).

Outcomes

Primary Outcomes

Not specified

Similar Trials